Exclusive: Pfizer vet grabs $25M seed round to 'integrate' machine learning, genomics tech in drug R&D

Having been involved in a number of attrition task force efforts during his tenure as European R&D chief at Pfizer, David Roblin tells me there’s a quote that resonates with him, uttered 20 years ago by South African biologist Sydney Brenner when he accepted a Nobel Prize.